380 related articles for article (PubMed ID: 33711782)
1. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
Respir Med; 2021; 180():106311. PubMed ID: 33711782
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
4. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
[TBL] [Abstract][Full Text] [Related]
5. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
[TBL] [Abstract][Full Text] [Related]
9. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
[TBL] [Abstract][Full Text] [Related]
10. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
Pelaia C; Crimi C; Crimi N; Ricciardi L; Scichilone N; Valenti G; Bonavita O; Andaloro S; Morini P; Rizzi A; Pelaia G
Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA
Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
Mangia PP; Gallo O; Ritrovato D; Pradelli L
Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
[TBL] [Abstract][Full Text] [Related]
13. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
de Llano LP; Naval E; Mejía N; Domínguez-Ortega J
Expert Rev Respir Med; 2022 Jan; 16(1):1-15. PubMed ID: 34783265
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
[TBL] [Abstract][Full Text] [Related]
17. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]